PET shows early response to hormone therapy in breast cancer

Share this article:

Molecular imaging of progesterone receptor status in breast tumors using positron emission tomography (PET) may be an effective and noninvasive means of identifying early in the course of endocrine, or hormone-based, therapy which patients will respond well to treatment. 

In a recent study, mice with mammary cell lines derived from breast tumors that were positive for estrogen receptor-alpha (ERα) and for progesterone receptor (PR) underwent small-animal (PET)/computed tomography (CT). 18F-fluoroestradiol (18F-FES)-PET was used to image ER status, 18F-fluoro furanyl norprogesterone (18F-FFNP)-PET was used to image PR status, and 18F-fluorodeoxyglucose (18F-FDG)-PET was used to image glucose uptake.

“PET has typically been used to identify the target for endocrine therapy in breast cancer by demonstrating that ER is present in tumors using [18F-FES-PET] or by monitoring for hormone-induced changes in tumor metabolism—“metabolic flare”—with [18F-FDG-PET] once therapy has begun,” explained the study's lead author, Amy M. Fowler, MD, PhD, of the Mallinckrodt Institute of Radiology at the Washington University School of Medicine in St. Louis, Missouri, in a statement issued by the Society of Nuclear Medicine. (Fowler's group's results were published in The Journal of Nuclear Medicine [2012;53(7):1119-1126], a publication of the Society of Nuclear Medicine.) “What is novel about our study is that we chose to image progesterone receptor levels to see how the estrogen signaling pathway is functioning in response to endocrine therapy.”

Primary mammary tumors and implanted tumors from the SSM2 and SSM3 mammary cell lines showed high uptake of 18F-FES and 18F-FFNP, and were confirmed to be ERα-positive and PR-positive. Classic estrogen-induced regulation of the PR gene was demonstrated by increased 18F-FFNP uptake of estradiol-treated SSM3 tumors.

Treatment with fulvestrant decreased 18F-FFNP, 18F-FES, and 18F-FDG uptake and inhibited growth of SSM3 tumors, but decreased only 18F-FES uptake in SSM2 tumors, with no effect on growth despite the fact that like the SSM3 tumors, the SSM2 tumors were also ERα-positive and PR-positive. Decreased 18F-FFNP uptake by SSM3 tumors occurred early after the start of therapy, before measurable tumor growth inhibition.

The results served to identify a profile that distinguished fulvestrant-sensitive from fulvestrant-resistant ERα-positive/PR-positive tumors before changes in tumor size, summarized the researchers. They added that based on this work, noninvasive imaging of baseline tumoral 18F-FES uptake and initial changes in 18F-FFNP uptake is a potentially useful strategy for identifying responders and nonresponders to endocrine therapy at an early stage.

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.

Immunotherapy added to radiotherapy may help overcome resistance to treatments

Coupling immunotherapy to radiotherapy treatment could help prevent cancers from becoming resistant to treatment, according to a new study.

Companion diagnostic test improves detection of BRCA mutations in patients with ovarian ...

The Tumor BRACAnalysis CDx companion diagnostic test boosted the detection of cancer-causing BRCA1/2 mutations in women with ovarian cancer by over 40 percent.